United Kingdom · Seed startup

Who invested in Oxford Drug Design

4 rounds we have observed, with the 0 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Raised 5 months ago

Funding summaryUpdated 26 Oct 2026

$3.3Mraised across 4 rounds since 2022, from 4 sources

$1.3MRound$328KRound$1.2MSeed$463KRound

Latest round: Round, $463KJun 2026
Biggest round: $1.3MRound · Jan 2022
Investors: 0

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20222023202420252026

$1.3MRound$328KRound$463KRound

First round: Round, $1.3M
Biggest round: $1.3M
Usual gap between rounds: 2 months

The rounds

Jun 2026
Round$463K
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Jun 2022
Seed$1.2M
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Mar 2022
Round$328K
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Jan 2022
Round$1.3M
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet

Founders and team

From Oxford Drug Design's own website: 5 on the team.

Dr. Alan D. RothChief Executive Officer
Dr. Paul FinnChief Scientific Officer
Dr. Mike DawsonHead of Biology
Dr. Richard CooperHead of ML & Methods Development
Sunil ShahMeet our Board of Directors

AdvisersDr. Michael MurphyProf. Xiang-Lei Yang

Also claim to have backed them

This firm lists Oxford Drug Design as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.